日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

针对妇科恶性肿瘤的白蛋白紫杉醇/贝伐单抗(AB160)纳米免疫偶联物治疗 I 期临床试验

Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Carrie A Strand, Lisa A Kottschade, Rachel A Kudgus, Sarah A Buhrow, Laura R Becher, Liyi Geng, Gretchen E Glaser, Megan E Grudem, Aminah Jatoi, Carolyn M Klampe, Amanika Kumar, Carrie L Langstraat, Robert R McWilliam

Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice

作者更正:部分抑制线粒体复合物 I 可改善 APP/PS1 雌性小鼠的阿尔茨海默病病理和认知功能

Stojakovic, Andrea; Trushin, Sergey; Sheu, Anthony; Khalili, Layla; Chang, Su-Youne; Li, Xing; Christensen, Trace; Salisbury, Jeffrey L; Geroux, Rachel E; Gateno, Benjamin; Flannery, Padraig J; Dehankar, Mrunal; Funk, Cory C; Wilkins, Jordan; Stepanova, Anna; O'Hagan, Tara; Galkin, Alexander; Nesbitt, Jarred; Zhu, Xiujuan; Tripathi, Utkarsh; Macura, Slobodan; Tchkonia, Tamar; Pirtskhalava, Tamar; Kirkland, James L; Kudgus, Rachel A; Schoon, Renee A; Reid, Joel M; Yamazaki, Yu; Kanekiyo, Takahisa; Zhang, Song; Nemutlu, Emirhan; Dzeja, Petras; Jaspersen, Adam; Kwon, Ye In Christopher; Lee, Michael K; Trushina, Eugenia

Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

恩多昔芬通过抑制 ERα+ 乳腺癌中的蛋白激酶 Cβ1 来下调 AKT 磷酸化

Swaathi Jayaraman #, Xinyan Wu #, Krishna R Kalari, Xiaojia Tang, Mary J Kuffel, Elizabeth S Bruinsma, Shahrzad Jalali, Kevin L Peterson, Cristina Correia, Rachel A Kudgus, Scott H Kaufmann, Santosh Renuse, James N Ingle, Joel M Reid, Matthew M Ames, Alan P Fields, Matthew J Schellenberg, John R Haw

Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury

血管内皮生长因子作为紫外线诱发皮肤损伤的早期激活剂

Stella P Hartono, Victoria M Bedell, Sk Kayum Alam, Madelyn O'Gorman, MaKayla Serres, Stephanie R Hall, Krishnendu Pal, Rachel A Kudgus, Priyabrata Mukherjee, Davis M Seelig, Alexander Meves, Debabrata Mukhopadhyay, Stephen C Ekker, Luke H Hoeppner

Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates

新型ATP敏感性钾通道开放剂Cromakalim前药1在正常血压犬和非人灵长类动物中的药理学特征和眼部降压作用

Roy Chowdhury, Uttio; Kudgus, Rachel A; Holman, Bradley H; Rinkoski, Tommy A; Hann, Cheryl R; Bahler, Cindy K; McCloud, Eric; Appt, Susan E; Reid, Joel M; Dosa, Peter I; Fautsch, Michael P

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

Wee1 抑制剂 Adavosertib (AZD1775) 与伊立替康联合治疗复发性实体瘤患儿的 I 期临床试验:COG I 期联合报告 (ADVL1312)

Kristina A Cole, Sharmistha Pal, Rachel A Kudgus, Heba Ijaz, Xiaowei Liu, Charles G Minard, Bruce R Pawel, John M Maris, Daphne A Haas-Kogan, Stephan D Voss, Stacey L Berg, Joel M Reid, Elizabeth Fox, Brenda J Weigel

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study

ADVL1522:一项针对复发或难治性肾母细胞瘤、横纹肌肉瘤、神经母细胞瘤、胸膜肺母细胞瘤、恶性周围神经鞘瘤或滑膜肉瘤患儿的洛沃妥珠单抗(IMGN901)II期研究——儿童肿瘤协作组研究

Geller, James I; Pressey, Joseph G; Smith, Malcolm A; Kudgus, Rachel A; Cajaiba, Mariana; Reid, Joel M; Hall, David; Barkauskas, Donald A; Voss, Stephen D; Cho, Steve Y; Berg, Stacey L; Dome, Jeffrey S; Fox, Elizabeth; Weigel, Brenda J

Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits

新型降眼压前药CKLP1在荷兰带状色素兔中的药理学和药代动力学特征

Roy Chowdhury, Uttio; Kudgus, Rachel A; Rinkoski, Tommy A; Holman, Bradley H; Bahler, Cindy K; Hann, Cheryl R; Reid, Joel M; Dosa, Peter I; Fautsch, Michael P

A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)

一项针对复发性或难治性实体瘤儿童和青少年的血管内皮生长因子受体酪氨酸激酶抑制剂阿昔替尼的研究:儿童肿瘤协作组 1 期和试点联盟试验 (ADVL1315)

Geller, James I; Fox, Elizabeth; Turpin, Brian K; Goldstein, Stuart L; Liu, Xiaowei; Minard, Charles G; Kudgus, Rachel A; Reid, Joel M; Berg, Stacey L; Weigel, Brenda J

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

儿童肿瘤协作组 (Children's Oncology Group) 报告了一项针对复发性或难治性实体瘤(包括中枢神经系统肿瘤)儿童和青少年患者的卡博替尼 I 期研究:ADVL1211 试验。

Chuk, Meredith K; Widemann, Brigitte C; Minard, Charles G; Liu, Xiaowei; Kim, AeRang; Bernhardt, Melanie Brooke; Kudgus, Rachel A; Reid, Joel M; Voss, Stephan D; Blaney, Susan; Fox, Elizabeth; Weigel, Brenda J